To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dualagonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their superior efficacies over monoagonist such as semaglutide, we determined cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the atomic level
They are administered subcutaneously, typically into the abdomen, thigh, or upper arm
Additionally, GLP-1 medications may alter how the kidneys handle electrolytes, creating a theoretical risk when combined with potassium-sparing agents
This dose is typically used at the start of treatment and may be increased gradually based on patient response
Erythrocyte deformability and its variation in diabetes mellitus
Drug Interactions Amlodipine: In vitro data in human plasma indicate that amlodipine has no effect on the protein binding of digoxin, phenytoin, warfarin, and indomethacin
